FDA's Grace McNally to Speak at ISPE Process Validation Conference

TAMPA, Fla., Oct. 1, 2012 /PRNewswire-USNewswire/ -- ISPE announced today that the FDA's Grace McNally will speak at the ISPE Process Validation Conference, taking place at the Sheraton Silver Spring Hotel in Silver Spring, Maryland USA on 17 – 18 October 2012.

(Logo: http://photos.prnewswire.com/prnh/20120912/DC73253LOGO)

McNally will speak about the FDA view of lifecycle approach implementation status and its application to legacy products. Her discussion will address recent process validation-related FDA warning letters and progress implementing the lifecycle approach to process validation in the industry and at FDA. McNally will also speak about interpretation of key aspects of the FDA Process Validation Guidance. Her presentation will be followed by a brief question-and-answer session, during which attendees can get direct answers to their questions about the FDA's updated standards for process validation.

McNally's presentation will be part of a two-day educational program focusing on practical implementation of the lifecycle approach to process validation. The conference will feature case studies and practical examples designed to teach attendees methods for saving time and money. Delegates will learn to utilize practical guidance for selecting and justifying an appropriate number of process validation batches and determining their stage 3 post-process validation manufacturing monitoring plan.

For more information on the ISPE Process Validation Conference, including detailed agendas and registration information, visit www.ISPE.org/2012ProcessValidation.

About ISPE
ISPE, the International Society for Pharmaceutical Engineering, is the world's largest not-for-profit association serving its Members through leading scientific, technical and regulatory advancement throughout the entire pharmaceutical lifecycle. The 20,000 Members of ISPE are building solutions in the development and manufacture of safe and effective pharmaceutical and biologic medicines and medical delivery devices in more than 90 countries around the world. Founded in 1980, ISPE has its worldwide headquarters in Tampa, Florida, USA and offices in Brussels, Belgium, Singapore and Shanghai, China. Visit www.ISPE.org for more information.

For more information contact:
Danielle Hould
ISPE Communications Manager
Tel: +1-813-960-2105, ext. 277
email: dhould@ispe.org
www.ISPE.org

SOURCE ISPE